Different doses of NNC0662-0419 for lowering blood sugar in type 2 diabetes
Tests NNC0662-0419 against semaglutide or placebo in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
Key facts
- Where
- Debrecen and Szeged, HungarySee the 2 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 75 with type 2 diabetes. It tests different doses of a new medicine, NNC0662-0419, against placebo or semaglutide.
- Age
- 18 to 75 years
- Sex
- Men and women (sex at birth)
- Disease stage
- Type 2 diabetes with an HbA1c of 7.0-10.0 percent (53-86 mmol/mol) at screening
- Earlier treatment
- No medicine for diabetes or obesity in the 90 days before screening. Short insulin treatment for up to 14 days in a row, and earlier insulin for gestational diabetes, is allowed.
- Biomarker or test result
- HbA1c of 7.0-10.0 percent (53-86 mmol/mol), measured by the central laboratory at screening
Main reasons for not taking part
- Treatment with other diabetes or obesity medicine within 90 days before screening
- Uncontrolled and possibly unstable diabetic retinopathy or maculopathy
- Known hypoglycaemic unawareness
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07415954, who can take part
Where in Hungary
- University of DebrecenDebrecen, HungaryNo longer taking part
- University of SzegedSzeged, HungaryNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07415954EU 2025-523260-20-00
- Record updated
- 11 September 2026
- Original description
This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.Read full original descriptionShow less
Efficacy and Safety of Once-weekly Subcutaneous NNC0662-0419 in Participants With Type 2 Diabetes - a Dose-finding Study
This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.
Inclusion: Male or female (sex at birth); Age 18-75 years (both inclusive) at the time of signing the informed consent; Glycated haemoglobin (HbA1c) of 7.0-10.0 percent (%) (53-86 millimoles per mole [mmol/mol]) (both inclusive) as assessed by central laboratory at screening; Willingness to obtain a high weight loss (greater than [>] 25% of weight at baseline).
Exclusion: Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed; Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination; Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's Questionnaire.